


# LEADING THE PLASTICS CIRCULAR ECONOMY



Update Conference Call \_ October 9, 2020

## DISCLAIMER

This presentation contains forward-looking statements about the Company's business and prospects. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future, which may not be accurate. This document is not to be reproduced by any person, nor to be distributed.

Such forward-looking statements also involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding the Company's financial position, business, regulatory strategy, plans and objectives of management for future operations (including development plans and objectives relating to our processes and products), are forward looking statements.

These statements may refer in particular to Carbios management's business strategy, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and contingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements. Carbios, its affiliates, directors, advisors, employees and representatives, expressly disclaim any liability whatsoever for such forward-looking statements. Carbios does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future events, or for any other reason and any opinion expressed in this presentation is subject to change without notice. Actual results could differ materially from those expressed in, or implied or projected by, forward-looking information and statements. These risks and uncertainties include those discussed or identified under Chapter 1.12. "Facteurs de Risques" in the Universal Registration Document (Document d'enregistrement universel) filed by Carbios with the French Market Authority ("AMF") on April 29th, 2020. This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of Carbios in any country.



#### AGENDA

- OUR AMBITION
- 2021 SITES REGROUPING ANNOUNCEMENT
  - **EVOLUTION OF CARBIOLICE SHARE CAPITAL**



3

#### AMBITION

Lead the transition towards sustainable plastics economy by developing technologies for the end of life of plastics


#### TECHNOLOGIES

nite recycling





# ENZYMES TO FULLY BREAKDOWN PLASTICS!







# CURRENT ORGANIZATION

#### Activities spread over several sites:

- \* R&D Center (St-Beauzire)
- Administrative Center (La Pardieu)
- Pilot plant (La Varenne)
- Demonstration Plant (St-Fons) -> Under transfer
- Carbiolice (Riom)
- Collaborative Research Center (Toulouse)





# OUR 2021 REGROUPING STRATEGY

#### Activities regrouped:

- Clermont-Ferrand (Michelin site) & Riom
  - ❖ R&D + Administration + Pilot Plant
    - + Demonstration Plant TechnipFMC
  - Carbiolice (Industrial production plant PLA biodegradation technology CARBICLICE
- Toulouse
  - Collaborative Research Center (enzymatic











Paris

Clermont-

Ferrand

Toulouse

# EVOLUTION OFCARBIOLICE SHARE CAPITAL

- A joint-venture created in 2016 by Carbios, Limagrain Ingredients and the SPI funds operated by Bpifrance:
  - **❖** Exclusive licensee of Carbios enzyme-based biodegradation technology
  - **❖** Fully operational Industrial Plant
  - **❖** Bpifrance committed to invest 11 M€ since creation of the JV
- Acquisition with a vast majority in shares:
  - ❖ Acquisition of Limagrain Ingredients' equity stake in the capital of Carbiolice by Carbios, is paid partly in cash and partly through the issuance of 100 000 new ordinary shares by Carbios
- Key rationale points of the acquisition:
  - **Simplified governance with only Bpifrance as a partner**
  - Increased majority shareholding by CARBIOS to 70%
  - **❖** Increased influence on Evanesto® technology commercial launch






# EVOLUTION OFCARBIOLICE SHARE CAPITAL

#### Main features of the share deal:

- Number of Shares: 100,000 representing 1.24% of Carbios' current share capital;
- Subscription Date: October 8, 2020;
- ❖ Standstill and lock-up Commitments: Until January 1<sup>st</sup>, 2021
- Conditions for the sale of Carbios shares at the end of the lock-up period: conditional until January 1<sup>st</sup>, 2022.








A FOURTH PHASE OF FUNDING OF €7.3 MILLION (Incl. €2,8 million from Carbios) IS PLANNED FOR 2020

)

#### ZERO IMPACT PLAstic

EVANESTO®, the world's first enzymatic biodegradation technology

Market launch imminent with a progressive ramp up





#### **HOW DOES IT WORK?** Step by step

#### **Evanesto® Production**



#### Evanesto® Inside





#### Evanesto® Activation







THE WORLD'S FIRST AND ONLY

BIOLOGICAL TECHNOLOGY TO

RECYCLE PET PLASTICS & FIBERS





## ■ HOW DOES IT WORK?







## BENEFITS OF THE TECHNOLOGY

- 100% yield recycling
- A process that can handle all forms of PET plastics (clear, colored, opaque, multi-layer...) and polyester fibers
- No inhibition of the enzyme by colorants, pigments, carbon black or other polymers (PE, PA, PVC...)
  - Depolymerization at low temperature (~70°C), atmospheric pressure, in water








CARBIOS' INNOVATION OFFERS THE POTENTIAL TO RECYCLE PET PLASTICS INFINITELY AND CONTRIBUTES TO ACHIEVING 100% RECYCLED PET CONTENT IN NEW PRODUCTS

#### ■ CARBIOS' NEXT STEPS

plastics







## APPENDIX





# INTELLECTUAL PROPERTY

**33 patent families** with worldwide patent pending applications





## WORLDWIDE EXCLUSIVE EXPLOITATION RIGHTS


On all results of R&D collaborations

#### A UNIQUE KNOW-HOW

In the development of bioprocesses combining enzymes & polymers

## A STRONG INTELLECTUAL PROPERTY

Protecting the applicative use of enzymes, processes and products



#### Patents granted in:

Europe, United-States, Canada, Mexico, China, Japan...



## SHARE & SHAREHOLDERS July 24<sup>th</sup>, 2020\*

\*: Shareholder structure after the Offering dated July 2020 (To the best knowledge of the Company)

**MARKET** Euronext Growth Paris

MNEMO/REUTERS/BLOOMBERG ALCRB / ALCRB.PA / ALCRB:FP

SHARES ISIN CODE FR0011648716

**NUMBER OF SHARES** 7.982.172

ICB CLASSIFICATION Chemistry / Speciality chemistry

Euronext Growth All-share, Euronext

INDICES Growth Bpifrance Innovation Index,

Enter Next PEA PME 150

FRENCH PEA-PME ELIGIBILITY Yes

**ANALYST COVERAGE** 



Baptiste de Leudeville




Xavier Regnard



Guillaume Cuvillier



Graeme Moyse









## ■ CASH FLOW STATEMENT

Cash flow (in thousand euros)	December 31, 2019	June 30, 2020
Cash at the opening	5,149	15,915
Net cash generated by operations	(3,036)	(1,721)
Net cash from investments	(2,406)	(1,595)
Net cash from financing operations	16,209	1,304
Change in cash	10,766	(2,012)
CLOSING CASH	15,915	13,903



# HALF-YEAR 2020 INCOME STATEMENT

(In thousand euros)	June 30, 2019	June 30, 2020
Operating revenue	702	849
Operating expenses	(2,717)	(3,567)
Operating Income	(2,015)	(2,718)
Financial Income	(8)	(50)
Current Income before Tax	(2,023)	(2,768)
Extraordinary profit (loss)	2	39
Income tax (Tax research credit)	310	469
NET INCOME (LOSS)	(1,711)	(2,260)



# SIMPLIFIED BALANCE SHEET

Assets (in thousand euros)	December 31, 2019	June 30, 2020
Intangible assets	858	1,011
Tangible assets	2,267	3,457
Assets in progress	148	240
Financial assets	12,027	12,084
Fixed Assets	15,300	16,792
Inventory	21	25
Receivables	1,065	1,149
Cash and marketable securities	15,915	13,903
Pre-paid expenses	75	132
Current Assets	17,076	15,209
Deferred financing costs	11	17
TOTAL ASSETS	32,386	32,017

<b>Liabilities &amp; Equity</b> (in thousand euros)	December 31, 2019	June 30, 2020
Shareholder's equity	22,005	20,300
Conditional advances	4,250	4,173
Loans	3,818	4,729
Trade payables and related accounts	1,387	1,360
Other liabilities	750	962
Prepaid income	176	494
Payables	6,131	7,545
TOTAL LIABILITIES & EQUITY	32,386	32,017



# AN EXPERIENCED MANAGEMENT TEAM



Jean-Claude LUMARET

Founder & CEO

40 years' experience in the international agro-industry and intellectual property expert

- TWB (Toulouse White Biotech): Chairman
- METABOLIC EXPLORER: VP Strategy & Innovation (Member of the Executive Committee)
- ROQUETTE: Director, Business Intelligence, Director BU Fermentation and Industrial Chemistry, Director, Intellectual Property and Regulatory Affairs
- Chemical Engineer, Lyon University, European Trademark Expert, CEIPI Center for International IP Study, Strasbourg



Martin STEPHAN

**Deputy CEO** 

30 years' experience in the chemical industry

- **CHEMOURS:** Global Director of the Fluorotelomers business, EMEA Director, Sourcing, Logistics & Real Estate
- **DU PONT DE NEMOURS**: Global Product Manager, Business and Market Manager, Sales Director
- ATOFINA: Global Business Manager Fluorotelomers
- **ELF ATOCHEM**: Various positions in Finance
- MS in Business Management, HEC Paris, BA Economics Paris University.



Kader HIDRA

Chief Financial Officer

Financial markets expert

- CITEGESTION (EDF): CEO of a digital start-up specialized in asset management and software development for Smart Cities
- EDF: Investor & Markets Director (Head of IR)
- MORGAN STANLEY: Utilities & Clean Energy Specialist Equity Sales
- **BERENBERG**: Utilities & Clean Energy Specialist
- Printing & Packaging Engineer (Ecole Polytechnique Grenoble), MBA from Duke University (Fuqua Business School).



Prof. Alain MARTY

Chief Scientific
Officer

International expert in enzymology and biological processes

- INSA Institut National des Sciences Appliquées, Toulouse: Professor and Head of a research group
- AERES Agence d'Evaluation de la Recherche et de l'Enseignement Supérieur and ANR Agence Nationale de la Recherche: Evaluator (France's National Education Research Agencies)
- PhD in Biology, Biochemical Engineer, University of Toulouse



## AN OPERATIONAL BOARD OF DIRECTORS



IAN HUDSON Chairman

- Ex President EMEA DuPont
- Ex Board member Europabio



TRUFFLE CAPITAL, REPRESENTED BY DR. PHILIPPE POULETTY

 Co-Founder & Executive Director of Truffle Capital



JEAN FALGOUX

- Ex Corp. Officer Ajinomoto Inc.
- Ex VP Ajinomoto Europe
- Ex Senior VP Hoechst Roussel



JACQUELINE LECOURTIER

- Ex General Director ANR (National Research Agency)
- Ex Scientific Director IFP (A Public Research Innovation Organization)



PASCAL JUERY

- President & CEO of Agfa-Gevaert
- Member of the Executive Committee of Solvay



JACQUES BREUIL

 Ex General Secretary of the Barbier Group



GODEFROY MOTTE

- Ex member of the Executive Committee of Eastman Chemical
- Former Chairman of Eastman Chemical Global holdings



ALAIN CHEVALLIER

- Partner Life Sciences, Truffle Capital
- Ex CFO Sanofi-Aventis France



23

## OUR KEY PARTNERS





































# OUR CONTRIBUTION TO THE UN SDGs













# "Designing the new plastic economy"